S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
HUMA · Humacyte, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$0.42
+0.01
(+3.35%)
● At close: October 21 at 4:00:00 PM EDT
$0.41
+0.00
(+0.00%)
Overnight:
10:51:16 PM EDT
DAY'S RANGE
$0.42
$0.39
$0.42
52-WEEK RANGE
$0.42
$0.34
$1.80
What's happening
- HUMA is up 3.35% today, trading at $0.42. — Live quote
- Volume today (80,056) is well below its 3-month average of 8,981,150. (Finnhub fundamentals)
- Reports earnings on 2026-11-06, 15 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.16 actual vs. $-0.10 estimated (-56.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
HUMA
-57.21%
vs S&P 500
-70.58%
1-YEAR RETURN
HUMA
-76.23%
vs S&P 500
-91.40%
6-MONTH RETURN
HUMA
-42.08%
3-MONTH RETURN
HUMA
-36.21%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.16
Est. $-0.10
MISS -56.9%
2026-04-26 (Q1 2026)
$-0.09
Est. $-0.12
BEAT +24.1%
2026-01-26 (Q4 2025)
$-0.13
Est. $-0.13
BEAT +3.2%
2025-10-26 (Q3 2025)
$-0.11
Est. $-0.16
BEAT +31.9%
Valuation Measures & Ratios
Enterprise Value4$100.5M
Forward P/E5—
PEG Ratio6-0.11
Price / Sales (TTM1)53.86
Price / Book76.73
EV4 / Revenue47.39
EV4 / EBITDA—
Profit Margin-4560.82%
Operating Margin-6290.62%
Return on Equity (ROE8)-516.75%
Return on Assets (ROA9)-84.76%
Avg Volume (3M)8,981,150
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $181.0M | $118.2M | $185.7M | $109.3M | $7.9M |
| P/E | -1.65 | -3.51 | -3.36 | -1.16 | -0.09 |
| Price/Sales | 92.57 | 57.23 | 118.22 | 133.64 | 15.36 |
| Price/Book | 5.79 | 10.17 | -39.09 | 26.98 | 0.22 |
| EV/Revenue | 70.28 | 51.10 | 105.81 | 87.15 | -106.20 |
| ROE | -350.56% | -289.47% | 1162.51% | -2329.32% | -245.88% |
| ROA | -79.36% | -30.43% | -60.36% | -68.00% | -54.52% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short29,399,293
Change from Prior Settlement-7.57%
% of Float—
Days to Cover (Short Ratio)7.31
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-07; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -4.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -4560.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -76.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on HUMA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $406.0K | $495.0K | $753.0K | $301.0K | $517.0K | $0 | $0 | $0 |
| Operating income | -$27.0M | -$28.9M | -$24.4M | -$29.7M | -$23.2M | -$30.2M | -$29.5M | -$26.6M |
| Net income | -$36.8M | -$17.6M | -$17.5M | -$37.7M | $39.1M | -$39.2M | -$56.7M | -$31.9M |
| EPS (diluted) | $-0.16 | $-0.09 | $-0.11 | $-0.24 | $0.28 | $-0.33 | $-0.48 | $-0.29 |
| EPS (basic) | $-0.16 | $-0.09 | $-0.11 | $-0.24 | $0.28 | $-0.33 | $-0.48 | $-0.29 |
| Operating margin | -$6.6K | -$5.8K | -$3.2K | -$9.9K | -$4.5K | — | — | — |
| Net margin | -$9.1K | -$3.6K | -$2.3K | -$12.5K | $7.6K | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $138.1M | $110.6M | $116.4M | $91.5M | $138.8M | $162.6M | $137.9M | $114.8M |
| Total liabilities | $106.8M | $98.9M | $113.3M | $96.3M | $134.7M | $126.5M | $190.5M | $178.5M |
| Stockholders' equity | $31.3M | $11.6M | $3.1M | -$4.8M | $4.1M | $36.0M | -$52.7M | -$63.7M |
| Total current assets | $92.8M | $63.6M | $67.8M | $41.4M | $51.7M | $73.7M | $47.9M | $23.0M |
| Total current liabilities | $14.9M | $16.2M | $18.4M | $25.6M | $21.1M | $20.0M | $20.0M | $20.9M |
| Cash & equivalents | $79.9M | $48.5M | $50.5M | $19.5M | $38.0M | $62.8M | $44.9M | $20.6M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $330.0K | $434.0K | $441.0K | $1.1M | $394.0K | $488.0K | $0 | — |
| Inventory | $7.0M | $9.9M | $13.6M | $18.4M | $11.1M | $8.0M | $0 | — |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $16.2M | $17.4M | $18.5M | $19.9M | $21.2M | $22.4M | $23.1M | $24.2M |
| Other non-current assets | $672.0K | $672.0K | $672.0K | $672.0K | $1.2M | $1.2M | $1.3M | $1.3M |
| Accounts payable | $4.2M | $5.1M | $5.4M | $9.6M | $6.6M | $5.6M | $4.5M | $6.9M |
| Accrued liabilities | $9.3M | $8.7M | $10.5M | $10.3M | $9.2M | $9.7M | $11.4M | $11.2M |
| Other current liabilities | — | — | $0 | $0 | $61.0K | $60.0K | $238.0K | — |
| Long-term debt | $36.3M | $35.9M | $35.4M | — | — | — | $0 | — |
| Other non-current liabilities | $2.1M | $1.7M | $1.6M | $520.0K | $984.0K | $951.0K | $983.0K | $1.4M |
| Common stock & paid-in capital | $28.0K | $23.0K | $20.0K | $16.0K | $16.0K | $16.0K | $13.0K | $12.0K |
| Retained earnings | -$781.3M | -$744.5M | -$726.8M | -$702.0M | -$684.5M | -$646.9M | -$686.0M | -$665.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.1M | -$25.1M | -$26.1M | -$23.9M | -$26.4M | -$28.6M | -$26.6M | -$22.9M |
| Investing cash flow | -$104.0K | -$175.0K | -$39.0K | -$49.0K | -$568.0K | -$228.0K | -$63.0K | -$934.0K |
| Financing cash flow | $53.5M | $23.3M | $57.2M | -$44.6M | $2.2M | $46.7M | $51.0M | $849.0K |
| Free cash flow | -$22.2M | -$25.3M | -$26.2M | -$24.0M | -$27.0M | -$28.8M | -$26.6M | -$23.8M |
| Capital expenditures | $104.0K | $175.0K | $39.0K | $49.0K | $568.0K | $228.0K | $63.0K | $934.0K |
| Share-based compensation | $2.6M | $3.2M | $2.5M | $2.5M | $2.3M | $2.5M | $1.7M | $1.6M |
| Change in accounts receivable | -$104.0K | -$7.0K | -$637.0K | $684.0K | -$94.0K | $308.0K | $0 | $0 |
| Change in inventory | -$2.3M | -$2.0M | $3.6M | $7.3M | $2.9M | $8.0M | $0 | $0 |
| Change in accounts payable | -$912.0K | -$362.0K | -$4.2M | $3.0M | $1.5M | $653.0K | -$2.4M | $1.1M |
| Debt repaid | — | — | — | $50.0M | — | — | — | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | — | — | — |
| Operating income | -$108.1M | -$114.4M | -$100.0M | -$84.6M | -$81.2M |
| Net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M | -$26.5M |
| EPS (diluted) | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 |
| EPS (basic) | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 |
| Operating margin | -$5.3K | — | — | — | — |
| Net margin | -$2.0K | — | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $116.4M | $137.9M | $128.2M | $204.3M | $286.5M |
| Total liabilities | $113.3M | $190.5M | $114.7M | $87.4M | $164.4M |
| Stockholders' equity | $3.1M | -$52.7M | $13.5M | $116.9M | $122.2M |
| Total current assets | $67.8M | $47.9M | $83.3M | $154.2M | $229.3M |
| Total current liabilities | $18.4M | $20.0M | $18.4M | $19.6M | $11.1M |
| Cash & equivalents | $50.5M | $44.9M | $80.4M | $149.8M | $217.5M |
| Marketable securities (current) | — | — | $0 | $2.1M | $8.0M |
| Accounts receivable | $441.0K | $0 | $0 | $31.0K | $176.0K |
| Inventory | $13.6M | $0 | — | — | — |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $18.5M | $23.1M | $26.8M | $30.0M | $35.0M |
| Other non-current assets | $672.0K | $1.3M | $632.0K | $682.0K | — |
| Accounts payable | $5.4M | $4.5M | $6.5M | $1.6M | $2.1M |
| Accrued liabilities | $10.5M | $11.4M | $9.3M | $7.1M | $6.8M |
| Other current liabilities | $0 | $238.0K | $53.0K | — | — |
| Long-term debt | $35.4M | $0 | — | — | $30.0M |
| Other non-current liabilities | $1.6M | $983.0K | $711.0K | $712.0K | — |
| Common stock & paid-in capital | $20.0K | $13.0K | $10.0K | $10.0K | $10.0K |
| Retained earnings | -$726.8M | -$686.0M | -$537.3M | -$426.5M | -$414.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$105.0M | -$98.1M | -$73.3M | -$71.1M | -$81.2M |
| Investing cash flow | -$884.0K | -$1.6M | -$173.0K | $4.8M | -$8.2M |
| Financing cash flow | $61.5M | $114.2M | $4.5M | -$1.4M | $267.0M |
| Free cash flow | -$105.9M | -$99.7M | -$75.6M | -$72.2M | -$81.4M |
| Capital expenditures | $884.0K | $1.6M | $2.3M | $1.0M | $220.0K |
| Share-based compensation | $9.8M | $6.1M | $6.8M | $6.2M | $10.1M |
| Change in accounts receivable | $261.0K | $0 | -$31.0K | -$145.0K | $63.0K |
| Change in inventory | $21.8M | $0 | — | — | — |
| Change in accounts payable | $973.0K | -$2.0M | $4.8M | -$509.0K | -$197.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding HUMA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers28.5%
Shares Outstanding234,182,284
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 10,107,679 | $7.9M | 4.32% | +41.2% | 2026-06-30 |
| ANTIPODES PARTNERS Ltd | 10,103,647 | $7.9M | 4.31% | +76.5% | 2026-08-06 |
| Alyeska Investment Group, L.P. | 6,022,925 | $4.7M | 2.57% | +0.0% | 2026-08-14 |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 5,000,000 | $3.9M | 2.14% | +0.0% | 2026-08-11 |
| BlackRock, Inc. | 4,839,929 | $3.8M | 2.07% | -60.7% | 2026-08-07 |
| GREAT POINT PARTNERS LLC | 3,750,000 | $2.9M | 1.60% | +0.0% | 2026-08-14 |
| UBS Group AG | 2,843,493 | $2.2M | 1.21% | +2.2% | 2026-08-13 |
| AQR CAPITAL MANAGEMENT LLC | 2,597,134 | $2.0M | 1.11% | +34.9% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,185,225 | $1.7M | 0.93% | -40.3% | 2026-08-12 |
| MILLENNIUM MANAGEMENT LLC | 1,909,049 | $1.5M | 0.82% | +1665.1% | 2026-08-14 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,699,243 | $1.3M | 0.73% | +60.6% | 2026-08-14 |
| CITADEL ADVISORS LLC | 1,443,376 | $1.1M | 0.62% | +0.0% | 2026-08-14 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,353,515 | $1.1M | 0.58% | +4.8% | 2026-08-14 |
| VANGUARD FIDUCIARY TRUST CO | 1,181,276 | $921.4K | 0.50% | +16.8% | 2026-06-30 |
| HRT FINANCIAL LP | 1,089,508 | $850 | 0.47% | +0.0% | 2026-08-14 |
| LPL Financial LLC | 1,025,535 | $800.3K | 0.44% | +18.6% | 2026-08-07 |
| GSA CAPITAL PARTNERS LLP | 1,005,709 | $785 | 0.43% | +302.5% | 2026-08-06 |
| Private Advisor Group, LLC | 965,091 | $753.2K | 0.41% | +15.9% | 2026-07-27 |
| State Street Corp | 842,537 | $657.5K | 0.36% | -72.3% | 2026-08-07 |
| HBK INVESTMENTS L P | 790,000 | $616.5K | 0.34% | +0.0% | 2026-08-14 |
| WEALTH EFFECTS LLC | 693,920 | $541.5K | 0.30% | +239.3% | 2026-08-06 |
| Lion Point Capital, LP | 650,000 | $507.3K | 0.28% | +0.0% | 2026-08-14 |
| LuminArx Capital Management LP | 650,000 | $507.3K | 0.28% | +0.0% | 2026-08-14 |
| Goldman Sachs Group Inc | 586,524 | $457.7K | 0.25% | -13.4% | 2026-08-14 |
| Bank Of America Corp /De/ | 578,592 | $451.3K | 0.25% | +46.1% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-16 to 2026-09-14
Recent transactions
- Insiders have net bought 26,044 shares over the last 182 days, across 5 purchases and 2 sales.
- Most recent: Jones Keith Anthony (Reporting person) — Open market purchase of 10,000 shares on 2026-09-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)117,818 sh(5 txns)
Sales (open market)91,774 sh(2 txns)
Net Shares+26,044
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Jones Keith Anthony | Reporting person | Open market purchase | 2026-09-14 | 10,000 |
| Sebelius Kathleen | Reporting person | Open market purchase | 2026-05-19 | 56,818 |
| Constantino Michael T. | Reporting person | Open market purchase | 2026-05-18 | 11,000 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off | Open market sale | 2026-05-18 | 45,887 |
| Parikh Shamik J | Chief Medical Officer | Open market sale | 2026-05-18 | 45,887 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Jones Keith Anthony | Reporting person | Open market purchase | 10,000 | $0.56 |
| 2026-08-20 | Jones Keith Anthony | Reporting person | Open market purchase | 10,000 | $0.69 |
| 2026-08-17 | Jones Keith Anthony | Reporting person | Open market purchase | 30,000 | $0.59 |
| 2026-05-19 | Sebelius Kathleen | Reporting person | Open market purchase | 56,818 | $0.88 |
| 2026-05-18 | Constantino Michael T. | Reporting person | Open market purchase | 11,000 | $0.89 |
| 2026-05-18 | Sander Dale A. | CFO and Chief Corp. Dev. Off | Open market sale | 45,887 | $0.90 |
| 2026-05-18 | Parikh Shamik J | Chief Medical Officer | Open market sale | 45,887 | $0.90 |
| 2025-11-16 | Sander Dale A. | CFO and Chief Corp. Deve. Off. | Grant / award | 311,100 | $0.00 |
| 2025-11-16 | Parikh Shamik J | Chief Medical Officer | Grant / award | 311,100 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:35 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-07 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-09-28 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-31 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about HUMA (Humacyte, Inc.). Links open the publisher — we don’t host full articles.
-
Starpharma (ASX: SPL) Advances First-in-Human HER2-Lu Study as Cash Runway Extends into FY28
Kalkine · 2026-10-22 -
Humacyte, Inc. (HUMA) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Yahoo · 2026-10-21 -
VERAXA Biotech (NASDAQ: VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pi
Benzinga · 2026-10-21 -
VivoSim Adds Human Disease Models for Drug Efficacy Tests | VIVS Stock News
Stock Titan · 2026-10-21 -
Cell Bio Human Tech Co.,Ltd's Equity Buyback announced on June 10, 2026, has expired with 167,284 shares, representing 2.02% for KRW 999.93 million.
www.marketscreener.com · 2026-10-21 -
Form 4 Freightos Ltd: Sesma Andrea Indave (VP, Human Resources) For: 16 October By Investing.com
Investing.com South Africa · 2026-10-21 -
Once Human Shares Server Info and Unlock Details For Isles of Abyss Expansion Update
MMORPG.com · 2026-10-20
No headlines in this category right now — try “All”.